ORIC — ORIC Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00
- $543.72m
- $335.54m
- 31
- 23
- 72
- 37
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 28.6 | 74.2 | 78.9 | 91.8 | 111 |
Operating Profit | -28.6 | -74.2 | -78.9 | -91.8 | -111 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -26.9 | -73.7 | -78.7 | -89.1 | -101 |
Net Income After Taxes | -26.9 | -73.7 | -78.7 | -89.1 | -101 |
Net Income Before Extraordinary Items | |||||
Net Income | -26.9 | -73.7 | -78.7 | -89.1 | -101 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -26.9 | -73.7 | -78.7 | -89.1 | -101 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.976 | -2.23 | -2.07 | -2.25 | -1.96 |
Dividends per Share |